Clinical Review of Pegylated Interferons Suggests Formulation
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
Treatment with ropeginterferon alfa-2b (P1101) generated responses and was well tolerated in patients with prefibrotic primary myelofibrosis or low- or intermediate-1–risk myelofibrosis per the Dynamic International Prognostic Scoring System (DIPSS), according to data from the ongoing phase 2 P1101MF trial (NCT04988815) presented at the 2023 EHA Congress.
TAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH for the registration and promotion of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), a rare blood cancer, in Brazil, Argentina, Colombia, Chile, Peru, Ecuador, and Mexico.
VIENNA--(BUSINESS WIRE)--With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comprehensive development program in PV is considered by many key opinion leaders as the most significant development in the field of PV treatment in the past 30 years.
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446, LuxSE: PHECA, PHECR), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have been updated to include BESREMi® (ropeginterferon alfa-2b-njft) as a preferred therapeutic option for the treatment of adults with both high and low-risk polycythemia vera (PV), regardless of treatment history.
PharmaEssentia’s first product Besremi is the only first-line treatment approved for polycythemia vera (PV). Now marketed for more than a year, the drugmaker is ready to take its message directly to consumers.
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey